ATE491453T1 - Verwendung von 4-aminochinolin-verbindungen zur behandlung entzündlicher erkrankungen des auges - Google Patents

Verwendung von 4-aminochinolin-verbindungen zur behandlung entzündlicher erkrankungen des auges

Info

Publication number
ATE491453T1
ATE491453T1 AT03752885T AT03752885T ATE491453T1 AT E491453 T1 ATE491453 T1 AT E491453T1 AT 03752885 T AT03752885 T AT 03752885T AT 03752885 T AT03752885 T AT 03752885T AT E491453 T1 ATE491453 T1 AT E491453T1
Authority
AT
Austria
Prior art keywords
eye
treatment
inflammatory diseases
aminoquinoline compounds
aminoquinoline
Prior art date
Application number
AT03752885T
Other languages
English (en)
Inventor
Rajeev Raut
Original Assignee
Rajeev Raut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rajeev Raut filed Critical Rajeev Raut
Application granted granted Critical
Publication of ATE491453T1 publication Critical patent/ATE491453T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
AT03752885T 2002-05-17 2003-05-14 Verwendung von 4-aminochinolin-verbindungen zur behandlung entzündlicher erkrankungen des auges ATE491453T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38092602P 2002-05-17 2002-05-17
PCT/IN2003/000189 WO2003097025A2 (en) 2002-05-17 2003-05-14 A process for preparing pharmaceutical compositions containing 4-aminoquinolines compounds for treatment of inflammatory disorders of the eye and compositions resulting therefrom

Publications (1)

Publication Number Publication Date
ATE491453T1 true ATE491453T1 (de) 2011-01-15

Family

ID=29550039

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03752885T ATE491453T1 (de) 2002-05-17 2003-05-14 Verwendung von 4-aminochinolin-verbindungen zur behandlung entzündlicher erkrankungen des auges

Country Status (7)

Country Link
US (1) US7084157B2 (de)
EP (1) EP1558254B1 (de)
AT (1) ATE491453T1 (de)
AU (1) AU2003249575A1 (de)
DE (1) DE60335404D1 (de)
PT (1) PT1558254E (de)
WO (1) WO2003097025A2 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8273366B2 (en) * 2002-06-05 2012-09-25 University Of Florida Research Foundation, Incorporated Ophthalmic drug delivery system
US20120058993A1 (en) * 2003-07-23 2012-03-08 Douglas Pharmaceuticals Ltd. Stable Suspension Formulation
GB0406014D0 (en) * 2004-03-17 2004-04-21 Arakis Ltd Pharmaceutical composition and use
WO2005115359A2 (en) * 2004-05-06 2005-12-08 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Methods and compositions for the treatment of uveitis
JP4239036B2 (ja) * 2005-02-21 2009-03-18 ラウト，ラジーブ 改良薬剤組成物
WO2006108666A1 (en) * 2005-04-13 2006-10-19 Proteosys Ag Mefloquine, nelfinavir and saquinavir as novel agents for neurodegenerative and (neuro-) inflammatory diseases
US9839667B2 (en) * 2005-10-14 2017-12-12 Allergan, Inc. Prevention and treatment of ocular side effects with a cyclosporin
NZ568694A (en) * 2005-11-09 2011-09-30 Zalicus Inc Method, compositions, and kits for the treatment of medical conditions
EP1983988A2 (de) * 2006-02-16 2008-10-29 The McLean Hospital Corporation Verfahren und zusammensetzungen zur behandlung von morbus parkinson
US20080125454A1 (en) * 2006-10-05 2008-05-29 Wyeth Methods and Compositions for Treatment of Scleritis and Related Disorders
WO2009089399A2 (en) * 2008-01-10 2009-07-16 Bausch & Lomb Incorporated Compositions comprising toll-like receptor or coreceptor antagonists and methods for ocular neuroprotection
WO2009089401A2 (en) * 2008-01-10 2009-07-16 Bausch & Lomb Incorporated Compositions comprising toll-like receptor or coreceptor antagonists and methods for treating or controlling ocular allergy using same
EP3334415A1 (de) * 2015-08-18 2018-06-20 Astellas Institute for Regenerative Medicine Klinische formulierungen
JP2020503377A (ja) 2016-12-13 2020-01-30 ベータ セラピューティクス プロプライアタリー リミティド ヘパラナーゼ阻害剤及びそれの使用
AU2017377659A1 (en) * 2016-12-13 2019-07-11 Beta Therapeutics Pty. Ltd. Methods of treating ocular disorders
US11787783B2 (en) 2016-12-13 2023-10-17 Beta Therapeutics Pty Ltd Heparanase inhibitors and use thereof
CN113318231A (zh) * 2020-02-28 2021-08-31 上海医药集团股份有限公司 一种4-氨基喹啉类化合物的应用
CN114796216A (zh) * 2022-01-04 2022-07-29 南京医科大学 甲氟喹在防治全身代谢性炎症疾病中的应用
CN114920694B (zh) * 2022-07-18 2022-11-08 康瑞鑫(天津)药物研究院有限公司 羟氯喹粗品的精制方法及制备的羟氯喹产品

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2498187A1 (fr) * 1981-01-16 1982-07-23 Rhone Poulenc Sante Procede de preparation d'amino-4 chloro-7 quinoleines
RO92640A2 (ro) * 1985-05-13 1987-09-30 Institutul De Medicina Si Farmacie,Ro Metoda pentru tratamentul keratitelor virotice
US5318780A (en) * 1991-10-30 1994-06-07 Mediventures Inc. Medical uses of in situ formed gels
CA2133620A1 (en) * 1993-10-28 1995-04-29 Werner Hofheinz Aminoquinoline derivatives
WO1997018193A1 (en) * 1995-11-16 1997-05-22 F. Hoffmann-La Roche Ag Antimalarial quinolin derivatives
US20020091139A1 (en) * 1997-10-17 2002-07-11 Damon Todd Holdings, L.L.C. Treatment and delivery of hydroxychloroquine
US6384081B2 (en) * 1998-10-09 2002-05-07 Charles L. Berman Treatment of diseases of the eye characterized by the formation of metalloproteinase
US6572858B1 (en) * 1999-04-30 2003-06-03 Apt Pharmaceuticals, Llc Uses for anti-malarial therapeutic agents
AR031135A1 (es) * 2000-10-10 2003-09-10 Upjohn Co Composiciones de antibiotico topico para el tratamiento de infecciones oculares
CA2466338C (en) * 2001-11-09 2010-01-12 Lauren Charous New uses for anti-malarial therapeutic agents

Also Published As

Publication number Publication date
WO2003097025A3 (en) 2004-02-12
US20030216431A1 (en) 2003-11-20
AU2003249575A8 (en) 2003-12-02
AU2003249575A1 (en) 2003-12-02
DE60335404D1 (de) 2011-01-27
EP1558254A2 (de) 2005-08-03
WO2003097025B1 (en) 2004-03-18
EP1558254B1 (de) 2010-12-15
PT1558254E (pt) 2011-02-15
WO2003097025A2 (en) 2003-11-27
US7084157B2 (en) 2006-08-01

Similar Documents

Publication Publication Date Title
ATE491453T1 (de) Verwendung von 4-aminochinolin-verbindungen zur behandlung entzündlicher erkrankungen des auges
EA200601239A1 (ru) Замещённые хинолиновые соединения
ATE440087T1 (de) 2,4-diaminopyrimidinderivate, die sich als inhibitoren von pkc-theta eignen
NO20063821L (no) Kinolinderivater for anvendelse som mykobakterielle inhibitorer
NO20055632L (no) Aromatiske oksyfenyl- og aromatiske sulfanylfenylderivater
HRP20050533A2 (en) Aminoindazole derivatives and use thereof as kinase inhibitors
EA200700934A1 (ru) Производные пиримидина и их применение в качестве модуляторов cb2
CY1109104T1 (el) 1,2,3,4 τετρα-υποκατεστημενη ινδολη για την αντιμετωπιση ασθενειων του αναπνευστικου
ATE389395T1 (de) Substituierte 2-aminotetraline zur vorbeugenden behandlung von morbus parkinson
EA200970637A1 (ru) 2-замещенные-6-гетероциклилпроизводные пиримидона в качестве ингибиторов тау-протеинкиназы
BRPI0411673A (pt) composto, sal farmaceuticamente aceitável, composição farmacêutica, e, uso de um composto
EA200601194A1 (ru) Новые производные бензофурана, используемые для профилактики или лечения нарушений, связанных с 5-ht-рецептором
EA200501399A1 (ru) Производные бензопирана, которые могут использоваться при лечении воспалительных заболеваний
NO20050270L (no) Nye forbindelser, deres anvendelse og fremstilling
ATE438617T1 (de) Substituierte cyclohexyl-1,4-diamin-derivate
EA201070367A1 (ru) Производное 6-пиримидинилпиримид-4-она
ATE524171T1 (de) Verwendung von 2-(2-nitro-4- trifluormethylbenzoyl)-1,3-cyclohexandion bei der behandlung der parkinson-krankheit
ATE371724T1 (de) Behandlung neurodegenerativer krankheiten
ATE392471T1 (de) Behandlung neurodegenerativer krankheiten durch verwendung von scd4-inhibitoren
EA200500133A1 (ru) Производные пирролидина в качестве антагонистов окситоцина
NO20054067L (no) Nye substituerte 2,3-benzodiazepinderivater.
EA200600115A1 (ru) Производные 2-аминобензойной кислоты
DE602008004741D1 (de) Thiophenderivate als medikamente zur behandlung von okularer hypertonie
ATE518853T1 (de) Verbindungen zur behandlung entzündlicher erkrankungen
EA200401432A1 (ru) Сложноэфирные производные декагидроизохинолин-3-карбоновой кислоты в качестве анальгетиков

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties